BioCryst Pharmaceuticals Announces Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) has announced its participation in several key investor conferences within the healthcare industry. These events play a crucial role in highlighting the company's progress and dedication to developing innovative treatments for rare diseases.
Details of Upcoming Conferences
BioCryst will be involved in the following important conferences:
Wells Fargo Healthcare Conference
The company is scheduled to present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 1:30 p.m. ET. This conference serves as a major platform for investors and representatives from the biotech and pharmaceutical fields to explore advancements and future opportunities.
H.C. Wainwright 26th Annual Global Investment Conference
Next, BioCryst will be featured at the H.C. Wainwright 26th Annual Global Investment Conference, taking place on Monday, September 9, 2024, at 9:00 a.m. ET. This event provides companies with a venue to share their biopharmaceutical strategies and growth potential.
Cantor Global Healthcare Conference
Furthermore, BioCryst will participate in the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET. This conference offers insights into ongoing innovations and the potential market impact of the latest therapeutic advancements focused on rare diseases.
Accessing Conference Presentations
Investors and interested individuals can access live audio webcasts of the presentations, along with replays, through the Investor Relations section of BioCryst's official website. This feature enables stakeholders who are unable to attend in person to stay updated on the company's latest developments and presentations.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a biotechnology company dedicated to creating innovative solutions for complement-mediated and other rare diseases. The firm specializes in structure-guided drug design, which facilitates the development of first-in-class or best-in-class therapeutic agents. One of its key products, ORLADEYO (berotralstat), is notable for being the first oral, once-daily plasma kallikrein inhibitor that aims to enhance treatment options for patients.
With a strong pipeline of small-molecule and protein therapies, BioCryst is committed to meeting the unmet medical needs in the complex area of rare diseases. The company's focus on commercializing existing therapies while advancing new candidates underscores its commitment to improving the lives of patients around the globe.
Contact Information
For additional inquiries, please contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Frequently Asked Questions
What is the purpose of BioCryst's presentations at these conferences?
The presentations are designed to highlight BioCryst's innovative therapies and engage with investors regarding the company's growth and strategic focus on treating rare diseases.
How can interested parties access the conference presentations?
Investors can access live audio webcasts and replays of the presentations through the Investor Relations section of BioCryst's official website.
What is ORLADEYO (berotralstat)?
ORLADEYO is BioCryst's first oral, once-daily plasma kallikrein inhibitor, aimed at providing new treatment options for patients affected by rare diseases related to dysfunction in the complement system.
What is the significance of the H.C. Wainwright Conference?
This annual event is significant as it allows leading companies in the biotechnology and healthcare sectors to present their innovations and strategic insights to potential investors and stakeholders.
Who should be contacted for further inquiries about BioCryst?
For additional inquiries, interested individuals can reach out to John Bluth using the provided phone number or email address.